Interleukin-2 liposomal

Drug Profile

Interleukin-2 liposomal

Alternative Names: IL-2 liposomal; Interleukin-2-liposomal - OncoTherapeutics; L-IL-2; Liposomal interleukin-2; Liposomal-IL-2; Liposome-encapsulated IL-2; Liposome-encapsulated interleukin-2; OncoLipin 2; OTx 287

Latest Information Update: 22 Jul 2005

Price : $50

At a glance

  • Originator University of Minnesota
  • Developer Biomira USA; Oncodigm BioPharma
  • Class Adjuvants; Antineoplastics; Interleukins; Lymphokines
  • Mechanism of Action Immunostimulants; Interleukin 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Suspended Cancer

Most Recent Events

  • 22 Jul 2005 Interleukin-2 liposomal is available for licensing outside of North America (http://www.biomira.com)
  • 24 May 2004 Oncodigm BioPharma is developing liposomal interleukin-2
  • 13 May 2003 Studies have been added to the Cancer therapeutic trials, pharmacodynamics, pharmacokinetics and overview section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top